Apogee Therapeutics (APGE) EBT (2022 - 2026)

Apogee Therapeutics (APGE) has reported EBT for 5 consecutive years, with -$74.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 33.98% year-over-year to -$74.0 million; the TTM figure through Mar 2026 stood at -$274.3 million (down 33.64% YoY), while the FY2025 annual figure was -$255.6 million, down 40.32% from the prior year.
• EBT fell to -$74.0 million in Q1 2026 per APGE's latest filing, from -$69.3 million in the prior quarter.
• Across five years, EBT topped out at -$1.8 million in Q2 2022 and bottomed at -$74.0 million in Q1 2026.
• Historically, EBT has averaged -$41.3 million across 5 years, with a median of -$41.4 million in 2024.
• Annual changes were most pronounced in 2023 — EBT plunged 939.92% — and 2025, when it declined 3.16%.
• Apogee Therapeutics' EBT stood at -$20.8 million in 2022, then sank by 197.92% to -$61.9 million in 2023, then retreated by 8.54% to -$67.2 million in 2024, then retreated by 3.16% to -$69.3 million in 2025, then declined by 6.79% to -$74.0 million in 2026.
• Business Quant data shows APGE's EBT at -$74.0 million in Q1 2026, -$69.3 million in Q4 2025, and -$65.0 million in Q3 2025.